

# Formulary Amendment Form

## (For use with Existing Formulary-Approved Medicines Only)

### A. Introduction

This form only applies to a medicine that is already approved for inpatient/day surgery use or has PBS approval for the new indication.

Application type*	Tick which is applicable, both may be applicable	Complete
Request a new formulation of an existing formulary medicine to be added to formulary	<input type="checkbox"/>	Sections B, C, E, F, G, H
Request to modify/add indications and/or prescribers for an existing formulary listing (e.g. adding PBS indications and/or changing prescriber restrictions)	<input type="checkbox"/>	Sections B, D, E, F, G, H

\* If both application types, complete all Sections B-H.

For requests to add drugs approved for reimbursement under Section 100, use the relevant customised [Formulary Form](#)

For all other Formulary requests, use the [Formulary Submission form](#)

For approval to use this drug on an individual patient basis, use the [IPU application form](#)

### B. Profile of Currently Approved Medicine

Active Ingredient Name(s)	
Trade/Brand Name	
Medicine Formulation(s) currently approved on formulary	
List current formulary approval (including restrictions)	
Is the medicine used for	<input type="checkbox"/> inpatients/day procedures only <input type="checkbox"/> outpatients only* <input type="checkbox"/> both inpatients and outpatients*

\*If, for outpatient and not subsidised by PBS, use the [Formulary Submission form](#)

### C. Request to add new formulation

What is the proposed new formulation?	
Trade/Brand name	
What is the recommended dose? Please indicate whether it is different to current formulation in use.	

**1. What are the perceived advantages of the new formulation?**

**2. Is the proposed use for the new formulation (e.g. indications, prescribers) the same as the current approved formulation?**

YES  NO If NO, also complete Section D.

**3. Is it proposed the old formulation(s) be removed from formulary?**

YES  NO

**4. If the new formulation is added to formulary, will there need to be a change in local documents e.g. guidelines, protocols, standing orders?**

YES, please provide more details below  NO  NOT KNOWN

### D. Request to modify indications and/or prescribers

**1. What/who are the proposed new indication(s) and/or prescribers?**

Proposed modification	Tick whichever is applicable (both may be applicable)	Detail proposed change
<i>Change to indications</i>	<input type="checkbox"/>	Are the new indication(s) PBS-approved? <input type="checkbox"/> Y / <input type="checkbox"/> N Is the medicine for inpatient or day procedure use only? <input type="checkbox"/> Y / <input type="checkbox"/> N
<i>Change to prescribers</i>	<input type="checkbox"/>	If applicable, do the proposed prescribers(s) meet PBS criteria? <input type="checkbox"/> Y / <input type="checkbox"/> N Should any existing prescriber group(s) be removed? <input type="checkbox"/> Y / <input type="checkbox"/> N

**2. What are the perceived advantages to modifying indications and/or prescribers?**

**3. If the proposed change(s) are added to formulary, will there need to be a change in local documents e.g. guidelines, protocols, standing orders?**

YES, please provide more details below  NO  NOT KNOWN

## E. Financial Implications

What are the comparative costs of proposed therapy changes versus current therapy)? (Current prices can be obtained from Pharmacy)

Therapy	Cost/patient/day (a)	Volume of use (patient numbers/ day) (b)	Duration (days) (c)	Total cost [(a x b) x c]
<i>Proposed therapy</i>				
<i>Current therapy</i>				
<i>Other current therapy, if applicable</i>				

List any other cost implications or advantages (including drugs which may be replaced; need for training; use of other devices).

## F. Safety Implications

List any medication safety implications, including design of packaging that may occur with proposed formulary amendment

## G. Conflicts of Interest

Financial or other interests resulting from contact with pharmaceutical companies, which may have a bearing on this submission:

- Gifts
- Travel expenses
- Samples
- Industry paid food/refreshments
- Honoraria
- Research support
- Nil conflict of interest
- Other support (describe below)

## H. Approval process

The following must be completed prior to submitting application to the DTC

### Details of Applicant making the request

Name of Applicant			
Position / Appointment			
Signature		Date	
E-mail address for correspondence			
Phone number			

### Endorsed by

(Must be completed by Head of Unit/Manager of Department)

Name of Unit Head/ Manager of Department			
Position / Appointment			
Signature		Date	

## H. Submission

Forward completed form to the Pharmacy department with supporting data and relevant protocol/guideline (if applicable).

For questions or discussions regarding this application, the Pharmacy Department may be contacted via:

Phone: [ ]

Email: [ ]

► *Forward completed form to the Pharmacy Department*

## For Drug and Therapeutics Committee Use Only

### Check List (New Formulation)

- Drug already on Formulary for indications requested
- No significant cost implications
- No significant safety implications
- Inpatient use only or ongoing supply available via PBS

### Check List (New indications/prescribers)

- Drug already on Formulary
- New indications/prescribers approved for supply under PBS
- No significant cost implications
- No significant safety implications

### Outcome of application process:

Process	Date / Details / Notes
Application received <i>(Date received by DTC secretary)</i>	
Application considered <i>(DTC meeting date)</i>	
Outcome:	<input type="checkbox"/> Approved  <input type="checkbox"/> Rejected  <input type="checkbox"/> Deferred
Conditions of approval <i>(Specify restrictions)</i>	
Approval review date <i>(If applicable)</i>	
Applicant advised of outcome <i>(Date)</i>	

### Approved by:

Signed on behalf of Drug and Therapeutics Committee	
Name	
Date	